Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Annovis Bio Inc ANVS

Healthcare Biotechnology
Annovis Bio, Inc. is a clinical-stage drug platform company addressing neurodegeneration such as Alzheimer’s disease (AD), Parkinson’s disease (PD) and other chronic neurodegenerative diseases. The Company is developing its lead product candidate, Buntanetap, which is designed to address AD, PD, and potentially other chronic neurodegenerative diseases. Buntanetap is a synthetically produced... see more

Recent & Breaking News (NYSE:ANVS)

/C O R R E C T I O N -- Today's Marketplace/

PR Newswire December 4, 2024

Annovis to Host Year-End Investor Webcast on December 11, 2024

GlobeNewswire November 25, 2024

Annovis Invited to Present at National Institute on Aging Workshop on Dementia with Lewy Bodies (DLB)

GlobeNewswire November 12, 2024

Annovis Bio Reports Third Quarter Financial Results and Provides Business Update

GlobeNewswire November 11, 2024

Annovis Bio Appoints Matthew Peterson, Ph.D., as Senior Clinical Scientist

GlobeNewswire November 7, 2024

Annovis to Highlight Buntanetap's Alzheimer's Research Progress with Presentations at CTAD 2024

GlobeNewswire October 22, 2024

FDA Clears Annovis to Launch Pivotal Phase 3 Alzheimer's Studies, Paving the Way to NDAs

GlobeNewswire October 15, 2024

Annovis Bio Inc. (NYSE: ANVS) Leading Way in Development of Safe, Effective Drugs for Neurodegenerative Diseases

GlobeNewswire October 3, 2024

Annovis Bio Inc. (NYSE: ANVS) Research Points to Potential Future Breakthroughs in AD Space Through Innovative Combinations

GlobeNewswire October 2, 2024

Annovis Files Three New Patents for Combination Therapies Involving Buntanetap, Trulicity, and Viagra

GlobeNewswire September 30, 2024

Annovis Bio (NYSE: ANVS) to Present at H.C. Wainwright 26th Annual Global Investment Conference

GlobeNewswire September 5, 2024

Annovis Bio Reports Second Quarter Financial Results and Provides Business Update

GlobeNewswire August 15, 2024

Annovis' Lead Compound Enhances Cognition Synergistically with GLP-1 Agonist

GlobeNewswire August 6, 2024

Annovis Bio Secures U.S. Patent for Treatment of Acute Traumatic Brain Injury with Buntanetap

GlobeNewswire July 24, 2024

Annovis Bio Receives FDA Approval to Transition to New Crystal Form of Buntanetap

GlobeNewswire July 16, 2024

Annovis Bio Welcomes Four New Executives to Strengthen Leadership Team

GlobeNewswire July 9, 2024

Annovis Bio Announces New Data from Phase III Parkinson's Study Highlighting Improvements in Unified Parkinson's Disease Rating Scale (MDS-UPDRS) and Cognition after Treatment with Buntanetap

GlobeNewswire July 2, 2024

Annovis Bio Files Provisional Patent for New Manufacturing Process of Crystalline Form of Buntanetap

GlobeNewswire June 27, 2024

Annovis Bio Files Patent for New Composition of Matter for Buntanetap

GlobeNewswire June 26, 2024

Annovis Bio Inc. (NYSE: ANVS) Schedules Investor Webcast to Discuss Parkinson's Disease Data

GlobeNewswire June 25, 2024